跳至主要内容
临床试验/NCT04179318
NCT04179318Unknown不适用

A Retrospective, International Multicenter, Single Arm Clinical Trial of the New Geneswell BCT in Vitro Diagnosis of Breast Cancer Prognosis

Second Affiliated Hospital, School of Medicine, Zhejiang University0 个研究点目标入组 100 人开始时间: 2020年2月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
100
主要终点
Comparative assessment between risk groups

研究概览

简要总结

Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.

This test provides prognostic information to assess the risk of recurrence. The BCT score calculated by geneswell BCT was associated with the risk of recurrence. The higher the BCT score, the more likely it is to relapse, and vice versa.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • The patients were diagnosed with invasive breast cancer with positive hormone receptor (including positive estrogen receptor or progesterone receptor) and negative human epidermal growth factor receptor 2 (HER2)
  • Axillary lymph node assessment : pN0 or PN1
  • Women aged 18 and over
  • Patients without chemotherapy after operation

排除标准

  • Patients with negative hormone receptor (both estrogen and progesterone receptor are negative)
  • Human epidermal growth factor receptor 2 (HER2) positive
  • Pathological nodule evaluation: pN2 or pN3
  • Male patients
  • Patients receiving chemotherapy after surgery

结局指标

主要结局

Comparative assessment between risk groups

时间窗: Month 9

By evaluating the 5-year disease-free survival rate (DFS) of patients in high and low risk groups, the statistical differences between the two groups were compared.

次要结局

未报告次要终点

研究者

发起方
Second Affiliated Hospital, School of Medicine, Zhejiang University
申办方类型
Other
责任方
Sponsor

相似试验